iosBio Pharma

Executive Summary

iosBio Pharma, a UK-based biotechnology company founded in 2014, is pioneering oral vaccine delivery through its proprietary OraPro™ and Enhanced Surface Display (ESD™) platforms, combined with AI-driven antigen design. The company's lead program targets Epstein-Barr Virus (EBV), a significant unmet medical need associated with infectious mononucleosis and several cancers. iosBio's thermostable, self-administered vaccines aim to eliminate cold-chain requirements and improve global vaccine accessibility. Currently in Phase 1 clinical development, iosBio is evaluating its EBV vaccine candidate's safety and immunogenicity in healthy volunteers. The platform's potential extends beyond EBV to other infectious diseases and oncology, offering a needle-free alternative to traditional injections. With a strong intellectual property position and a focus on high-need indications, iosBio represents an attractive opportunity in the drug delivery space. However, as a private company with limited public data, investment risk remains elevated. The company's next major value inflection points include Phase 1 data readout and potential strategic partnerships.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 EBV Vaccine Top-Line Data60% success
• Q4 2026Strategic Partnership or Licensing Deal50% success
• Q2 2027IND Filing for Second Indication (e.g., CMV or oncology)40% success